🇺🇸 FDA
Patent

US 7968511

Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis

granted A61KA61K31/137A61K38/02

Quick answer

US patent 7968511 (Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon Jun 23 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue Jun 28 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 23 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/137, A61K38/02, A61P, A61P25/00